UK prostate cancer diagnostic and therapeutic market was valued at $845.5 million in 2025 and is projected to reach $1,971.3 million by 2035, growing at a CAGR of 8.9% during the forecast period (2026-2035). The emergence of next-generation immunotherapies such as VIR-5500 is creating a strong growth catalyst for the global prostate cancer therapeutics market. Prostate cancer remains the most commonly diagnosed cancer among men in several countries, including the UK, with approximately 1.5 million new cases diagnosed each year globally. According to Cancer Research UK, more than 12,000 men die annually in the UK from the disease, indicating the urgent need for more effective and durable treatment options. Historically, prostate cancer has been considered an immune-cold tumor, meaning it has shown limited responsiveness to conventional immunotherapy approaches. This limitation has constrained innovation within advanced-stage treatment pathways, particularly for patients who no longer respond to hormone therapy, chemotherapy, or androgen receptor–targeted agents. However, early-stage clinical data presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in 2026 indicate a potential shift in this paradigm.
Browse the full report description of “UK Prostate Cancer Diagnosis & Treatment Market Size, Share & Trends Analysis Report by Diagnostic Technique (Prostate Specific Antigen Test, Digital Rectal Exam), by Therapy (Hormonal Therapy, Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy) Forecast Period, 2026–2035” a https://www.omrglobal.com/industry-reports/us-prostate-cancer-diagnostic-therapeutic-market
VIR-5500, an engineered T-cell engager developed by Vir Biotechnology, demonstrated encouraging results in a Phase I trial involving 58 men with advanced, treatment-resistant prostate cancer. At the highest tested dose, 82% of patients experienced a prostate-specific antigen (PSA) reduction of at least 50%, 53% achieved a reduction of 90% or more, and 29% saw PSA levels decline by at least 99%. Additionally, among patients with measurable tumors, nearly half showed tumor shrinkage, including a case where multiple metastatic liver lesions completely resolved after six treatment cycles. Importantly, 88% of participants experienced only mild side effects, addressing a key safety concern historically associated with T-cell engager therapies. These findings, while preliminary and pending peer review, signal the potential introduction of a new immunotherapy class within prostate cancer treatment algorithms. The ability of VIR-5500 to activate selectively within tumor environments may reduce systemic toxicity and improve treatment durability, which could enhance adoption rates across advanced care settings if validated in larger trials.
Innovation Leaders Transforming the UK Prostate Cancer Diagnostic and Therapeutic Market
The key players in the UK prostate cancer diagnostic and therapeutic market include Roche, Novartis, Pfizer, Johnson & Johnson, AstraZeneca, among others. These companies are driving innovation in the prostate cancer market through the development of next-generation immunotherapies, PSMA-targeted radiopharmaceuticals, precision imaging agents, and advanced molecular diagnostic platforms. Their focus on improving treatment efficacy, enhancing safety profiles, enabling earlier and more accurate detection, and supporting personalized therapy approaches is accelerating progress in advanced and metastatic prostate cancer care across global healthcare markets.
Market Coverage
Key questions addressed by the report.
UK Prostate Cancer Diagnostic and Therapeutic Market Report Segment
By Diagnostic Technique
By Therapeutics
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/us-prostate-cancer-diagnostic-therapeutic-market